Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000776 · ClinicalTrials.gov registry record · Phase 2
Dexamethasone in Cryptococcal Meningitis
A Phase 2 study of HIV Infections and Meningitis, Cryptococcal, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 14
- Study locations
NCT00000776: Completed Phase 2 study of HIV Infections and Meningitis, Cryptococcal, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00000776 is a Phase 2 study of HIV Infections and Meningitis, Cryptococcal that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 36 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (92% lower). The trial reports 14 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000776, a Phase 2 study of HIV Infections and Meningitis, Cryptococcal, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 14
- Study locations
Study Summary
To evaluate the effect of corticosteroids on reducing elevated intracranial pressure in cryptococcal meningitis. To evaluate the safety of corticosteroids in patients with cryptococcal meningitis and intracranial hypertension. In AIDS patients with cryptococcal meningitis, a correlation has been found between early death and elevated intracranial pressure. Since dexamethasone has been found to reduce intracranial pressure resulting from other forms of meningitis, it may be of benefit in AIDS patients with cryptococcal meningitis.
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Fluconazole
- DRUG Amphotericin B
- DRUG Flucytosine
Study Locations (14)
New York
- SUNY / Health Sciences Ctr at Brooklyn - Brooklyn
- SUNY / Erie County Med Ctr at Buffalo - Buffalo
- Beth Israel Med Ctr - New York
- Mount Sinai Med Ctr - New York
- Bronx Municipal Hosp Ctr/Jacobi Med Ctr - The Bronx
- Jack Weiler Hosp / Bronx Municipal Hosp - The Bronx
- Bronx Veterans Administration / Mount Sinai Hosp - The Bronx
Illinois
- Northwestern Univ Med School - Chicago
- Cook County Hosp - Chicago
Alabama
- Univ of Alabama at Birmingham - Birmingham
District of Columbia
- Georgetown Univ Med Ctr - Washington D.C.
Florida
- Univ of Miami School of Medicine - Miami
Ohio
- Ohio State Univ Hosp Clinic - Columbus
Other
- Univ of Puerto Rico - San Juan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Est. Completion | 1996-09 |
| Phase | Phase 2 |
What the finished NCT00000776 record still lists
NCT00000776 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 4 interventions - of which Dexamethasone is the first listed.
NCT00000776 lists 14 locations in 7 states (New York, Illinois, Alabama).
Frequently Asked Questions
What is clinical trial NCT00000776 about?
NCT00000776 is a clinical study titled "Dexamethasone in Cryptococcal Meningitis". To evaluate the effect of corticosteroids on reducing elevated intracranial pressure in cryptococcal meningitis. To evaluate the safety of corticosteroids in patients with cryptococcal meningitis and intracranial hypertension. In AIDS patients with cryptococcal meningitis, a correlation has been fo...
What is the current status of trial NCT00000776?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. Estimated completion is 1996-09.
What conditions does trial NCT00000776 study?
This clinical trial studies the following conditions: HIV Infections, Meningitis, Cryptococcal.
What interventions are being tested in trial NCT00000776?
The interventions under investigation include: Dexamethasone (DRUG), Fluconazole (DRUG), Amphotericin B (DRUG), Flucytosine (DRUG).
Who is sponsoring clinical trial NCT00000776?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00000776 being conducted?
This trial has 14 study locations across Alabama, District of Columbia, Florida, Illinois, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00000776's enrollment target sits among peer trials
36 406th of 542 higher than 131 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer